Literature DB >> 33609760

The risk-adjusted Charlson comorbidity index as a new predictor of one-year mortality rate in elderly Chinese patients who underwent hip fracture surgery.

Fei Xing1, Rong Luo1, Wei Chen1, Xiang Zhou2.   

Abstract

INTRODUCTION: Recently, many studies used the Charlson comorbidity index (CCI) to predict the postoperative mortality rate of elderly patients with hip fractures. However, as a predictor, CCI did not include other preoperative risk factors, resulting in decreasing its predictive value. Therefore, we performed a study to focus on two questions as follows: (1) What is the one-year mortality rate of elderly Chinese patients who underwent surgery for hip fracture? (2) Could risk-adjusted CCI act as a new predictor to predict the one-year mortality rate? HYPOTHESIS: The risk-adjusted CCI could exhibit a good predictive value for one-year mortality of elderly Chinese patients who underwent surgery for hip fracture.
MATERIAL AND METHODS: This retrospective observational cohort study is based on data collected from July 2012 to April 2016. Patients aged 65 years and older who underwent hip fracture surgery were included. The clinical patient data were obtained, including gender, age, BMI, types of fracture, smoking, injury side, time from injury to surgery, and CCI. Stepwise, multiple logistic regression analysis was used to identify risk factors contributed to the occurrence of postoperative death at one-year follow-up. The risk-adjusted CCI scores of patients were calculated by the formula based on the coefficient regression and independent variables. Receiver operating characteristic (ROC) curve analysis was used for determining the diagnostic value of different factors.
RESULTS: A total of 445 elderly patients who underwent surgery for hip fracture, including 171 males and 274 females, were enrolled in the study cohort. The mean CCI scores of all enrolled patients were 1.20±1.62. Sixty-four patients died within one year, and the one-year mortality rate was 14.38%. The multivariate logistic regression analysis reported that age, time from injury to surgery, and CCI were associated with death after surgical treatment within one year. The risk-adjusted CCI scores of patients=0.099×age (years)+0.355×time from injury to surgery (days)+0.434×CCI scores. The predictive value of the risk-adjusted CCI was highest among these risk predictors, whose AUC value was 0.816. DISCUSSION: The risk-adjusted Charlson comorbidity index could be used as a guide to predict one-year mortality rate in elderly Chinese patients after the surgical treatment of hip fractures. LEVEL OF EVIDENCE: III; cohort comparative study.
Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Charlson comorbidity index; Hip fracture; Mortality rate; Predictor; Risk factors

Mesh:

Year:  2021        PMID: 33609760     DOI: 10.1016/j.otsr.2021.102860

Source DB:  PubMed          Journal:  Orthop Traumatol Surg Res        ISSN: 1877-0568            Impact factor:   2.256


  4 in total

1.  Risk factors of mortality and second fracture after elderly hip fracture surgery in Shanghai, China.

Authors:  Minmin Chen; Yanping Du; Wenjing Tang; Weijia Yu; Huilin Li; Songbai Zheng; Qun Cheng
Journal:  J Bone Miner Metab       Date:  2022-08-08       Impact factor: 2.976

2.  A New Random Forest Algorithm-Based Prediction Model of Post-operative Mortality in Geriatric Patients With Hip Fractures.

Authors:  Fei Xing; Rong Luo; Ming Liu; Zongke Zhou; Zhou Xiang; Xin Duan
Journal:  Front Med (Lausanne)       Date:  2022-05-11

3.  The Role of Smoking and Body Mass Index in Mortality Risk Assessment for Geriatric Hip Fracture Patients.

Authors:  Ariana T Meltzer-Bruhn; Garrett W Esper; Christopher G Herbosa; Abhishek Ganta; Kenneth A Egol; Sanjit R Konda
Journal:  Cureus       Date:  2022-07-08

4.  Efficacy and safety of tranexamic acid for patients with intertrochanteric fractures treated with intramedullary fixation: A systematic review and meta-analysis of current evidence in randomized controlled trials.

Authors:  Jiabao Jiang; Fei Xing; Man Zhe; Rong Luo; Jiawei Xu; Xin Duan; Zhou Xiang
Journal:  Front Pharmacol       Date:  2022-09-19       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.